The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.
Esther CW Breij
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
David Satijn
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Sandra Verploegen
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Bart de Goeij
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Danita Schuurhuis
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Wim Bleeker
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Mischa Houtkamp
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Paul Parren
Employment or Leadership Position - Genmab
Stock Ownership - Genmab